quemliclustat + nab-paclitaxel + gemcitabine

This is a **combination therapy** involving quemliclustat (a small molecule CD73 inhibitor), nab-paclitaxel (an albumin-bound formulation of paclitaxel), and gemcitabine (a nucleoside analog chemotherapeutic). Quemliclustat inhibits CD73, reducing adenosine production in the tumor microenvironment—a pathway exploited by tumors to evade immune response, particularly relevant in KRAS-mutated cancers such as pancreatic ductal adenocarcinoma. Nab-paclitaxel disrupts microtubule function as a cytotoxic agent, and gemcitabine inhibits DNA synthesis as an antimetabolite. This regimen is under **phase 3 clinical investigation** as a first-line treatment for metastatic pancreatic cancer[1][3][7].

Brand names

quemliclustat

Other names

quemliclustat plus nab-paclitaxel plus gemcitabinequemliclustat + Gem-NP